European Journal of Clinical Pharmacology

, Volume 71, Issue 1, pp 1–13 | Cite as

Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review

  • Joana Magalhães
  • António Teixeira Rodrigues
  • Fátima Roque
  • Adolfo Figueiras
  • Amílcar Falcão
  • Maria Teresa Herdeiro
Review Article

Abstract

Purpose

The aim of this review is to assess the extent of the use of off-label and/or unlicenced drugs among hospitalised children.

Methods

A systematic search was made in MEDLINE-PubMED for papers published from 1994 to 2012, addressing the prescription of off-label and/or unlicenced drugs for the paediatric population in hospital care.

Results

Of the 829 studies retrieved, 34 met the inclusion criteria. Prescriptions ranged from 12.2 to 70.6 % for off-label and from 0.2 to 47.9 % for unlicensed drugs. The percentage of children who received at least one off-label and/or unlicensed drug ranged from 42.0 to 100 %, with newborns being the population that received most of such drugs. Off-label prescriptions were essential for dose modification (7.1–73.1 %) and unlicensed prescriptions for formulation modification purposes (3.6–100 %).

Conclusions

These findings show that: (i) off-label and/or an unlicensed prescribing is widespread among the hospitalised paediatric population worldwide, (ii) there is no consensus on a definition of off-label and/or unlicensed drugs and (iii) preterm newborns receive most off-label and/or unlicensed drugs. By shedding new light on off-label and/or unlicensed drug prescribing, these findings will hopefully contribute to generating new, more effective knowledge about the paediatric population’s need for quality drugs that are both safe and efficacious.

Keywords

Paediatric Unlicensed Off-label Drug Hospital care 

References

  1. 1.
    Official Journal of the European Union, Brussels. EC (2006) Regulation (EC) N0 1901/2006 of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.Google Scholar
  2. 2.
    Kimland E, Odlind V (2012) Off-label drug use in pediatric patients. Clin Pharmacol Ther 91(5):796–801PubMedCrossRefGoogle Scholar
  3. 3.
    Yewale VN, Dharmapalan D (2012) Promoting appropriate use of drugs in children. Int J Pediatr 2012:906570PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF et al (2007) Stimulation programs for pediatric drug research—do children really benefit? Eur J Pediatr 166(8):849–855PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Lass J, Naelapää K, Shah U, Käär R, Varendi H, Turner MA et al (2012) Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatr 12:136PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Kumar P, Walker JK, Hurt KM, Bennett KM, Grosshans N, Fotis MA (2008) Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. J Pediatr 152(3):412–415PubMedCrossRefGoogle Scholar
  7. 7.
    Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164(9):552–558PubMedCrossRefGoogle Scholar
  8. 8.
    Rocchi F, Paolucci P, Ceci A, Rossi P (2010) The European paediatric legislation: benefits and perspectives. Ital J Pediatr 36:56PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C et al (2006) Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol 62(11):947–952PubMedCrossRefGoogle Scholar
  10. 10.
    Posthumus AAG, Alingh CCW, Zwaan CCM, van Grootheest KK, Hanff LLM, Witjes BBCM et al (2012) Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study. BMJ Open 2(4):e000934PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Haffner S, Von Laue N, Wirth S, Thürmann PA (2005) Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values. Drug Saf 28(5):453–464PubMedCrossRefGoogle Scholar
  12. 12.
    Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1):77–83PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Schirm E, Tobi H, Van Puijenbroek EP, Monster-Simons MH, Van den berg DeJong LTW (2004) Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmacoepidemiol Drug Saf 13(3):159–165PubMedCrossRefGoogle Scholar
  14. 14.
    Ufer M, Kimland E, Bergman U (2004) Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 13(3):147–152PubMedCrossRefGoogle Scholar
  15. 15.
    Horen B, Montastruc J-L, Lapeyre-mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54(6):665–670PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88(9):965–968PubMedCrossRefGoogle Scholar
  17. 17.
    ICH Topic E 11 Clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). European Medicines Agency; 2001.Google Scholar
  18. 18.
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013. Oslo; 2012.Google Scholar
  19. 19.
    Turner S, Longworth A, Nunn AJ, Choonara I (1998) Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 316(7128):343–345PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1999 Mar;80(2):F142–144; discussion F144–145.Google Scholar
  21. 21.
    Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320(7227):79–82PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    t Jong GW, Vulto AG, De Hoog M, Schimmel KJ, Tibboel D, Van den Anker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 108(5):1089–1093CrossRefGoogle Scholar
  23. 23.
    Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M et al (2002) Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 91(3):339–347PubMedCrossRefGoogle Scholar
  24. 24.
    Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R et al (2002) Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol 19(2):67–72PubMedCrossRefGoogle Scholar
  25. 25.
    ’t Jong GW, Van der Linden PD, Bakker EM, Van der Lely N, Eland IA, Stricker BHC et al (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58(4):293–297PubMedCrossRefGoogle Scholar
  26. 26.
    O’Donnell CPF, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 110(5):e52–e52PubMedCrossRefGoogle Scholar
  27. 27.
    Carvalho PRA, Carvalho CG, Alievi PT, Martinbiancho J, Trotta EA (2003) Identificação de medicamentos ‘não apropriados para crianças” em prescrições de unidade de tratamento intensivo pediátrica. J Pediatr 79:397–402CrossRefGoogle Scholar
  28. 28.
    López Martínez R, Cabañas Poy MJ, Oliveras Arenas M, Clemente BS (2005) Utilización de medicamentos en una UCI neonatal: estudio prospectivo. Farm Hosp 29(1):26–29PubMedCrossRefGoogle Scholar
  29. 29.
    Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R et al (2005) Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol 61(10):775–779PubMedCrossRefGoogle Scholar
  30. 30.
    Di Paolo E, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M et al (2006) Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly 136(13–14):218–222PubMedGoogle Scholar
  31. 31.
    Eiland LS, Knight P (2006) Evaluating the off-label use of medications in children. Am J Health Syst Pharm 63(11):1062–1065PubMedCrossRefGoogle Scholar
  32. 32.
    Dell’Aera M, Gasbarro A, Padovano M, Laforgia N, Capodiferro D, Solarino B et al (2007) Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 29(4):361–367PubMedCrossRefGoogle Scholar
  33. 33.
    Jain S, Bavdekar SB, Gogtay N, Sadawarte P (2008) Off-label drug use in children. Indian J Pediatr 75(11):1133–1136PubMedCrossRefGoogle Scholar
  34. 34.
    Santos D, Clavenna A, Bonati M, Coelho H (2008) Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol 64(11):1111–1118PubMedCrossRefGoogle Scholar
  35. 35.
    Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34(3):277–287PubMedCrossRefGoogle Scholar
  36. 36.
    Bavdekar SB, Sadawarte P, Gogtay N, Jain S, Jadhav S (2009) Off-label drug use in a pediatric intensive care unit. Indian J Pediatr 76(11):1113–1118PubMedCrossRefGoogle Scholar
  37. 37.
    Neubert A, Lukas K, Leis T, Dormann H, Brune K, Rascher W (2010) Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol 66(1):87–95PubMedCrossRefGoogle Scholar
  38. 38.
    Morales-Carpi C, Estañ L, Rubio E, Lurbe E, Morales-Olivas F (2010) Drug utilization and off-label drug use among Spanish emergency room paediatric patients. Eur J Clin Pharmacol 66(3):315–320PubMedCrossRefGoogle Scholar
  39. 39.
    Dessì A, Salemi C, Fanos V, Cuzzolin L (2010) Drug treatments in a neonatal setting: focus on the off-label use in the first month of life. Pharm World Sci 32(2):120–124PubMedCrossRefGoogle Scholar
  40. 40.
    Doherty D, Pascuet E, Ni A, Stewart P, Splinter W, Vaillancourt R (2010) Off-label drug use in pediatric anesthesia and intensive care according to official and pediatric reference formularies. Can J Anesth 57(12):1078–1088PubMedCrossRefGoogle Scholar
  41. 41.
    Nguyen K-A, Claris O, Kassai B (2011) Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr 100(4):615–617PubMedCrossRefGoogle Scholar
  42. 42.
    Khdour M, Hallak H, Alayasa K, AlShahed Q, Hawwa A, McElnay J (2011) Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine. Int J Clin Pharm 33(4):650–655PubMedCrossRefGoogle Scholar
  43. 43.
    Van den Berg H, Tak N (2011) Licensing and labelling of drugs in a paediatric oncology ward. Br J Clin Pharmacol 72(3):474–481PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Lass J, Käär R, Jõgi K, Varendi H, Metsvaht T, Lutsar I (2011) Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol 67(12):1263–1271PubMedCrossRefGoogle Scholar
  45. 45.
    de Ferreira L, da Ibiapina CC, Machado MGP, Fagundes EDT (2012) A alta prevalência de prescrições de medicamentos off-label e não licenciados em unidade de terapia intensiva pediátrica brasileira. Rev Assoc Med Bras 58:82–87CrossRefGoogle Scholar
  46. 46.
    Oguz SS, Kanmaz HG, Dilmen U (2012) Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study. Int J Clin Pharm 34(1):136–141PubMedCrossRefGoogle Scholar
  47. 47.
    Dos Santos L, Heineck I (2012) Drug utilization study in pediatric prescriptions of a university hospital in southern brazil: off-label, unlicensed and high-alert medications. Farm Hosp 36(4):180–186PubMedCrossRefGoogle Scholar
  48. 48.
    Palčevski G, Skočibušić N, Vlahović-Palčevski V (2012) Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol 68(7):1073–1077PubMedCrossRefGoogle Scholar
  49. 49.
    Kimland E, Nydert P, Odlind V, Böttiger Y, Lindemalm S (2012) Paediatric drug use with focus on off-label prescriptions at Swedish hospitals—a nationwide study. Acta Paediatr 101(7):772–778PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes M Jr, Procianoy RS, Silveira RC (2012) Uso de medicamentos off-label e não licenciados em unidade de tratamento intensivo neonatal e sua associação com escores de gravidade. J Pediatr 88:465–470Google Scholar
  51. 51.
    Ballard CD, Peterson GM, Thompson AJ, Beggs SA (2013) Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health 49(1):38–42PubMedCrossRefGoogle Scholar
  52. 52.
    Maltz LA, Klugman D, Spaeder MC, Wessel DL (2013) Off-label drug use in a single-center pediatric cardiac intensive care unit. World J Pediatr Congenit Heart Surg 4(3):262–266PubMedCrossRefGoogle Scholar
  53. 53.
    Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr et al (2007) Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 161(3):282–290PubMedCrossRefGoogle Scholar
  54. 54.
    Hsu B, Brazelton T (2009) Off-label medication use in an academic hospital pediatric critical care unit. WMJ 108(7):343–348PubMedGoogle Scholar
  55. 55.
    Neubert A, Wong ICK, Bonifazi A, Catapano M, Felisi M, Baiardi P et al (2008) Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 58(5–6):316–322PubMedCrossRefGoogle Scholar
  56. 56.
    Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Saf 25(1):1–5PubMedCrossRefGoogle Scholar
  57. 57.
    Rocchi F, Tomasi P (2011) The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res 64(3):169–175PubMedCrossRefGoogle Scholar
  58. 58.
    Baiardi P, Ceci A, Felisi M, Cantarutti L, Girotto S, Sturkenboom M et al (2010) In-label and off-label use of respiratory drugs in the Italian paediatric population. Acta Paediatr 99(4):544–549PubMedCrossRefGoogle Scholar
  59. 59.
    Jong GW’t, Eland IA, Sturkenboom MCJM, Van den Anker JN, Stricker BHC (2004) Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J 23(2):310–313PubMedCrossRefGoogle Scholar
  60. 60.
    Sen EF, Verhamme KMC, Neubert A, Hsia Y, Murray M, Felisi M et al (2011) Assessment of pediatric asthma drug use in three European countries; a TEDDY study. Eur J Pediatr 170(1):81–92PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Zanon D, Gallelli L, Rovere F, Paparazzo R, Maximova N, Lazzerini M et al (2013) Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy. Eur J Pediatr 172(3):361–367PubMedCrossRefGoogle Scholar
  62. 62.
    Cuzzolin L, Zaccaron A, Fanos V (2003) Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 17(1):125–131PubMedCrossRefGoogle Scholar
  63. 63.
    Conroy S (2002) Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 4(6):353–359PubMedCrossRefGoogle Scholar
  64. 64.
    European Union. Better medicines for children from concept to reality—PROGRESS REPORT ON THE PAEDIATRIC REGULATION (EC) N°1901/2006. 2013Google Scholar
  65. 65.
    Mukattash T, Hawwa AF, Trew K, McElnay JC (2011) Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 67(5):449–461PubMedCrossRefGoogle Scholar
  66. 66.
    Jonville-Béra AP, Béra F, Autret-Leca E (2005) Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. Eur J Clin Pharmacol 61(3):231–236PubMedCrossRefGoogle Scholar
  67. 67.
    Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W et al (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 27(13):1059–1067PubMedCrossRefGoogle Scholar
  68. 68.
    Milne C-P, Bruss JB (2008) The economics of pediatric formulation development for off-patent drugs. Clin Ther 30(11):2133–2145PubMedCrossRefGoogle Scholar
  69. 69.
    Napoleone E (2010) Children and ADRs (adverse drug reactions). Ital J Pediatr 36:4PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Joana Magalhães
    • 1
    • 2
  • António Teixeira Rodrigues
    • 1
    • 2
  • Fátima Roque
    • 1
    • 3
  • Adolfo Figueiras
    • 4
    • 5
  • Amílcar Falcão
    • 2
    • 6
  • Maria Teresa Herdeiro
    • 1
    • 7
  1. 1.Centre for Cell BiologyUniversity of Aveiro (CBC/UA)AveiroPortugal
  2. 2.Faculty of Pharmacy, Health Sciences CampusUniversity of CoimbraCoimbraPortugal
  3. 3.Research Unit for Inland DevelopmentPolytechnic Institute of Guarda(UDI/IPG)GuardaPortugal
  4. 4.University of Santiago de CompostelaSantiago de CompostelaSpain
  5. 5.Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública—CIBERESP)MadridSpain
  6. 6.Centre for Neuroscience and Cell BiologyUniversity of Coimbra (CNC/UC)CoimbraPortugal
  7. 7.CESPUInstituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeGandraPortugal

Personalised recommendations